-
SAMHSA/CSAT. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004. PMID: 22514846.
-
ASAM. The ASAM National Practice Guideline For the Treatment of Opioid Use Disorder 2020 Focused Update. 2020.
-
SAMHSA. Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update. Winter 2016.
-
Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: A Rapid Review. J Gen Intern Med. December 2020;35(Suppl 3):954-963. doi:10.1007/s11606-020-06257-4. PMCID: PMC7728943. PMID: 33145687.
-
FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. FSMB Website. 2013.
-
USDHHS. Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements. 2016.
-
Farmer CM, Lindsay D, Williams J, et al. Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process. Subst Abuse. 2015;36(2):209-216. doi:10.1080/08897077.2015.1012613. PMCID: PMC4470850. PMID: 25844527.
-
SAMHSA. Screening, Brief Intervention, and Referral to Treatment (SBIRT). 2014.
-
Hale D, Viner R. Trends in the Prevalence of Multiple Substance Use in Adolescents in England, 1998-2009. J of Public Health, Oxford. 2013;35(3):367-374. PMID: 23528672.
-
Farmer C, Lindsay D, Williams J, et al. Practice Guidelines for Burprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process. 2015;36(2).
-
Strain E. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain. 2AD;18(4 Suppl)(S14-27). PMID: 12479251.
-
Kidorf M, Disney E, King V, et al. Prevalence of Psychiatric and Substance Use Disorders in Opioid Abusers in a Community Syringe Exchange Program. Drug Alcohol Depend. 2004;74(2):115-122. PMID: 15099655.
-
UMBCtube. SBIRT: Screen for Substance Use – Negative Screen. UMBCtube; 2011.
-
FDA. CLIA – Clinical laboratory improvement amendments – currently waived analytes. 2021.
-
Richert T, Johnson B. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden. Harm Reduct J. February 18, 2015;12. doi:10.1186/s12954-015-0037-2. PMCID: PMC4337060. PMID: 25889208.
-
VA/DoD. Management of Substance Use Disorder (SUD) (2015) – VA/DoD Clinical Practice Guidelines. 2015.
-
Klimas J, Field C-A, Cullen W, et al. Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users: Cochrane Review. Syst Rev. January 12, 2013;2.
-
Gudin J, Mogali S, Jones J. Risks, Management, and Monitoring of Combination Opioid, Benzodiazepines, and/or Alcohol Use. Postgrad Med. 2013;125(4):115-130. PMCID: PMC4057040. PMID: 23933900.
-
Sterling S, Chi F, Hinman A. Integrating Care for People With Co-Occurring Alcohol and Other Drug, Medical, and Mental Health Conditions. Alcohol Res Health. 2011;33(4):338-349.
-
FDA. Medication Guide: Zubsolv Sublingual Tablet (CIII). July 2013.
-
Kraus M, Alford D, Kotz M, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. J Addict Med. 2011;5(4):254-263.
-
Brands B, Blake J, Sproule B, et al. Prescription Opioid Abuse in Patients Presenting for Methadone Maintenance Treatment. Drug Alcohol Depend. 2004;73(2):199-207. PMID: 14725960.
-
Moore B, Fiellin D, Barry D, et al. Primary Care Office-Based Buprenorphine Treatment: Comparison of Heroin and Prescription Opioid Dependent Patients. J Gen Intern Med. 2007;22:527-530. PMCID: PMC1829433. PMID: 17372805.
-
Nielsen S, Hillhouse M, Thomas C. A Comparison of Buprenorphine Taper Outcomes between Prescription Opioid and Heroin Users. J Addict Med. 2013;7(1):33-38. PMCID: PMC3567310. PMID: 23222095.
-
Potter J, Marino E, Hillhouse M. Buprenorphine/Naloxone and Methadone Maintenance Treatment Outcomes for Opioid Analgesic, Heroin, and Combined Users: Findings from Starting Treatment with Agonist Replacement Therapies (START). J Stud Alcohol Drugs. 2013;74(4):605-613. PMCID: PMC3711351. PMID: 23739025.
-
Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.; 2020.
-
Eggleston W, Clark K, Marraffa J. Loperamide abuse associated with cardiac dysrhythmia and death. Ann Emerg Med. 2016. doi:http://dx.doi.org/10.1016/j.annemergmed.2016.03.047.
-
Kleber H, Weiss R, Anton R, et al. Practice guideline for the treatment of patients with substance use disorders. Vol 3rd edition. American Psychiatric Association; 2010.
-
Renner J, Saxon A, Levounis P. Buprenorphine Update and Evolving Standards of Care. IPS: The Mental Health Services Conference. October 2015. New York City.
-
Harned M, Sloan P. Safety Concerns with Long-Term Opioid Use. Expert Opin Drug Saf. 2016;15(7):955-962. PMID: 27070052.
-
Marshall P. Physical Functional Ability Questionnaire (FAQ5). In: In: Assessment and Management of Chronic Pain. Vol 14. 5th edition. Institute for Clinical Systems Improvement; 2011:Appendix C:99.
-
Erdemoglu A, Koc R. Brief Pain Inventory Score Identifying and Discriminating Neuropathic and Nociceptive Pain. Acta Neurol Scand. 2013;128(5):351-358. PMID: 23594114.
-
Fishbain D, Cole B, Lewis J, et al. What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review. Pain Med. 2008;9(4):444-459. PMID: 18489635.
-
ASAM. 2020 National Practice Guideline. Am Soc Addict Med. 2020.
-
Reisfield GM, Maschke KJ. Urine Drug Testing in Long-Term Opioid Therapy: Ethical Considerations. Clin J Pain. August 2014;30(8):679-684. doi:10.1097/01.ajp.0000435448.34761.c9. PMID: 24281293.
-
Gourlay D. Urine Drug Testing in Chronic Pain: A Patient Centered Approach (AMA) [webinar]. 2013.
-
American Society of Addiction Medicine (ASAM). Drug Testing As A Component Of Addiction Treatment and Monitoring Programs and in Other Clinical Settings. ASAM.org. 2010.
-
SAMHSA. Clinical Drug Testing in Primary Care. SAMHSA Website. 2012.
-
Romano G, Barbera N, Spadaro G, et al. Determination of Drugs of Abuse in Hair: Evaluation of External Heroin Contamination and Risk of False Positives. Forensic Sci Int. 2003;131(2-3):98-102.
-
Wu L, Woody G, Yang C, et al. Subtypes of Nonmedical Opioid Users: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2010;112:69-80. PMCID: PMC2967592. PMID: 20580168.
-
USPSTF. Unhealthy Alcohol Use in Adolescents and Adults, Including Pregnant Women: Screening and Behavioral Counseling Interventions – US Preventive Services Task Force. 2018.
-
Hasin D, Liu X-H, Nunes E, et al. Effects of Major Depression on Remission and Relapse of Substance Dependence. Arch Gen Psychiatry. 2002;59:375-380.
-
Fishman M, Wu L, Woody G. Buprenorphine for Prescription Opioid Addiction in a Patient With Depression and Alcohol Dependence. Am J Psychiatry. 2011;168(7):675-679. PMCID: PMC3178807. PMID: 21724673.
-
Fiellin D, Rosenheck R, Kosten T. Office-Based Treatment for Opioid Dependence: Reaching New Patient Populations. Am J Psychiatry. 2001;158(8):1200-1204.
-
Mee-Lee D. The ASAM Criteria. Vol 3rd edition. ASAM; 2013.
-
McClellan A, McKay J. Components of successful addiction treatment. In: N: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine. Vol Third Edition. Chevy Chase, Md: American Society of Addiction Medicine; 2003:3.
-
Stine S, Greenwald M, Kosten T. Pharmacologic interventions for opioid addiction. In: In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine. Vol Third Edition. Chevy Chase, Md; 2003.
-
Fishman M, Mee-Lee D, Schulman G, et al. Supplement to the ASAM Patient Placement Criteria on the Management of Alcohol Use Disorders. Baltimore, MD: Lippincott, Williams & Wilkins, Inc; 2010.
-
VA/DoD. Management of Substance Use Disorder (SUD) (2015). VA/DoD. 2015.
-
Jones H, Fischer G, Heil S. Maternal Opioid Treatment: Human Experimental Research (MOTHER) – approach, issues and lessons learned. Addiction. 2012;107:28-35.
-
Hopfer C, Khuri E, Crowley T, et al. Adolescent Heroin Use: A Review of the Descriptive and Treatment Literature. J Subst Abuse Treat. 2002;23(3):231-237. PMID: 12392810.
-
SAMHSA. Treatment of Adolescents With Substance Use Disorders. Treatment Improvement Protocol Series, No. 32. Rockville, Md: Center For Substance Abuse Treatment; 1999.
-
Conigliaro J, Reyes C, Parran T, et al. Principles of screening and early intervention. In: In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine. Vol Third Edition. Chevy Chase, Md: American Society of Addiction Medicine; 2003.
-
CADCA. Comprehensive Addiction and Recovery Act (CARA). CADCA.org. 2016.
-
Madras B, Wilson M, Avula D, et al. Screening, Brief Interventions, Referral to Treatment (SBIRT) for Illicit Drug and Alcohol Use at Multiple Healthcare Sites: Comparison at Intake and Six Months. Drug Alcohol Depend. 2010;99(1-3):280-295. PMCID: <a href=”https://www.ncbi.nlm.nih.gov/pmc/articles/PMC276
